Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Combination of GPR40 agonist and GLP-1 agonist improves glucose control in type 2 diabetes

Aug. 25, 2014

ViaCyte and Janssen enter rights agreement for type 1 diabetes cell therapy

Aug. 22, 2014

AM-9514, a GK activator with good pharmacokinetic profile in vivo

Aug. 22, 2014

Amicus Therapeutics reports phase III data for migalastat in Fabry disease

Aug. 22, 2014

Isis Pharmaceuticals to begin phase III trial in familial chylomicronemia syndrome

Aug. 21, 2014

FDA approves Genzyme's eliglustat for Type 1 Gaucher disease

Aug. 20, 2014

FDA approves IND for ViaCyte's stem cell therapy for type 1 diabetes

Aug. 20, 2014

New CETP inhibitors patented by Chong Kun Dang Holdings

Aug. 20, 2014

Amgen reports results from second phase III trial of AMG-416 in SHPT

Aug. 20, 2014

Eli Lilly and Boehringer Ingelheim's insulin glargine receives tentative approval from the FDA

Aug. 19, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...